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Abstract
Background: The present study was undertaken to determine the rate of occurrence of Human cytomegalovirus
(HCMV) among kidney transplant recipients and donors by application of direct detection methods and to
understand HCMV infection/disease development among transplanted patients as a prospective study.
Results: Peripheral blood samples collected from 76 kidney donors and 76 recipients from September 2007 to
August 2009 were subjected to pp65 antigenemia and Quantitative real-time PCR (qRT-PCR) assays. Data were
analyzed under Group A, B and C. Group A was further divided into sub-groups I, II, III, IV, and V for better
understanding. Three, one and two donors in sub-group I, III, IV of Group A tested positive for real time PCR
respectively. One recipient from group III tested positive for HCMV by qRT- PCR prior transplantation and
remained positive one month post-transplantation. Three other recipients, tested negative prior to transplantation
became positive a month after transplantation. Group B consisted of 18 donor-recipient pairs and one of the donor
tested positive for HCMV by qRT-PCR. Eight recipients tested positive for HCMV one month after transplantation. The
pp65 positivity and HCMV DNA load was high among group C recipients who mostly had symptoms of active
disease. Significantly high values of pp65 antigenemia were observed among recipients of sub-group II
(non-parametric chi-square test p = 0.007). Positive correlation between pp65 antigenemia and qRT-PCR value was
observed. Thirty three of the recipients with disease treated with Valgancyclovir showed improved clinical outcome.
Conclusion: Our study showed that a significant proportion of kidney recipients develop HCMV infection following
renal transplantation in spite of the absence of HCMV among donors. pp65 antigenemia assay and qRT- PCR
methods can be applied to detect HCMV among kidney donors and recipients to monitor development of disease
and these assays were predicative of HCMV infection among them. Clinical resistant to valganciclovir was not
observed.
Background
Human Cytomegalovirus causes significant morbidity
and mortality in immunocompromised patients, who
have undergone solid organ or bone marrow transplan-
tation [1,2]. Due to a depressed immune system, CMV-
related disease may be much more aggressive in kidney
transplanted patients. HCMV is one of the causes for
the failure of the graft [3]. The presence of latent
HCMV in both donors and recipients could be a source
of HCMV infection among kidney transplant recipients
[4]. It was Hughes in 2008, who showed the impact of
donor recipient sero-status on CMV antigenemia in a
large cohort of renal transplant recipients [3]. As donors
are potential sources of HCMV infection, a positive
HCMV detection in them, should prompt close moni-
toring of the recipients for the development of this viral
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an increase in the antiviral prophylaxis, there has been a
decline in reduction in morbidity and mortality caused
by this virus [5]. Since unwanted exposure to gancyclo-
vir results in development of gancyclovir resistance, the
preemptive strategy is widely followed. Though the
occurrence of HCMV disease is reduced markedly
among transplant recipients during the therapeutic per-
iod, the infection/disease has been reported on withdra-
wal of the drugs. Sensitive and specific diagnostic
methods are needed not only for the early detection of
HCMV infection in transplanted patient to initiate the
therapy, but also to continuously monitor them if
needed thereafter. Because of the latent life long HCMV
infection many transplant patients secrete HCMV with-
out any clinical disease and therefore the mere detection
of HCMV does not always indicate the need for treat-
ment. Quantitation of systemic HCMV load may pro-
vide a highly sensitive and specific method to have
insight to predict which of these patients may develop
HCMV disease. The present study was undertaken to
determine the rate of detection of HCMV among kidney
donors and recipients by application of pp65 antigene-
mia and quantitative real - time PCR. Investigations are
still going on to determine the exact relationship
between HCMV DNA and pp65 antigenemia levels. We
have also studied the relative diagnostic value of real
time PCR (qRT-PCR) with pp65 antigenemia. The
importance of correlating the test results with clinical
symptoms is given.
Results
A total of 57 donor recipient pairs were included in the
study. Based on the availability of follow-up samples,
they were classified into Group A and Group B. Recipi-
ents from whom peripheral blood samples could be
obtained at one month and after were classified under
Group A. Mean follow up days is 92.6 days. Group A
was further classified into five subgroups I-V based on
the pp65 and qRT- PCR values. Recipients from whom
one month post transplant sample could be obtained
were classified under group B. Nineteen more unrelated
donors and kidney recipients were included under
group C in the study. (Table 1). In group A, sub-group I
consisted of three donors positive for HCMV only by
real time PCR whose copy numbers were 1, 144 and
289 copy/ml. The recipients were tested negative for
HCMV before transplantation and by 30 days post
transplantation they turned positive with, 2265 copies/
ml, 119 copies/ml and, 25 copies/ml by real time PCR.
None were positive for pp65 antigenemia.
Twenty six recipients (69.2%) whose pre-transplant
samples along with the corresponding donor’s blood,
tested negative by both the methods used were classified
Table 1 Analysis of results of tests performed for detection of HCMV with the donor-renal recipient patients
Groups Donor/Recipient No of pairs positive by real time PCR No of pairs positive for pp65 antigenemia
Group A *D+/PRR-/PSR+ 3/3 0/3
Sub-Group I
Sub-Group II D-/PRR-/PSR+ 26/26 15
$/26
Sub-Group III *D+/PRR+/PSR+ 1/1 0/1
Sub-Group IV *D+/PRR-/PSR- 2/2 0/2
Sub-Group V D-/PRR-/PSR- 0/7 0/7
Group B D-/PRR-/PSR+ 6
#/18 2/18
D+/PPR-/PSR+ 1/18 0/18
Group C PSR+ 19
^/19 19/19
D+ 4/19 0/19
In Group A,
*- Donor (D), pre transplantation renal recipient (PRR) and post-transplant recipient (PSR) samples.
- Post transplant recipients were tested for HCMV infections by pp65 antigenemia and viraemia by real-time PCR.
- All the donors were pp65 antigenemia negative indicating that they were not infective.
- * Six donors belonging to sub-groups I, III and IV were positive for HCMV by real time - PCR with copy numbers ranging from 1 to 537 copies/ml were all
negative for HCMV DNA.
Group B consisted of donors from whom sampling was not possible after one month
of renal transplantation.
Group C consisted of unrelated donors and recipients.
- # Two among the recipients were positive for pp65 antigenemia also.
-^All 19 positive for HCMV DNA were also positive for pp65 antigenemia also.
-$All 15 patients samples positive for pp65 antigenemia were also positive for real time
PCR also.
- Eleven more were positive only by real time PCR assay.
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HCMV one month after transplantation. Among the 26,
15 patients were tested positive for both pp65 antigene-
m i aa n dr e a l-t i m eP C R .T h eh i g h e s tc o p yn u m b e r
detected by real - time PCR was 29, 768 copies/ml and
lowest was 4 copies/ml. The highest positive pp65 cell
count recorded among them was 78 cells and the lowest
was 3 cells. In eleven others, the blood sample was posi-
tive only by real - time PCR. The highest copy number
recorded in among seven of them was 3079 copies/ml
and lowest was 4 copies/ml. Mean pp65 antigenemia
values/2 × 10
5 PBLs for this group was 13.8.
Sub-group III consisted of a single patient whose pre-
transplantation sample had a real time count of
8 copies/ml which reduced to 7 copies/ml after a month
of transplantation. The corresponding donor was also
found positive for HCMV viremia with 11 copies/ml.
Sub-group IV consisted of two patient whose donors
were tested positive for HCMV. Two donors were posi-
tive for real time PCR with 86 copies/ml and 537
copies/ml respectively. The corresponding recipient was
negative for HCMV before and one month after
transplantation.
Sub-Group V consisted of seven recipients (15.4%)
whose donors, their pre-transplant specimens and three-
month post-transplant specimens were negative for both
pp65 antigenemia and real time PCR assay.
There was statistical difference in the pp65 antigene-
mia values among the three sub-groups (non-parametric
chi-square test p = 0.007, Figure 1,2,3). Significantly a
high value of pp65 antigenemia was observed among the
recipients belonging to sub-group II (Figure 4).
Of the (table 2) 18 donor-recipient pairs under Group
B, six recipients were tested positive for HCMV DNA
one month after transplantation by real-time PCR of
which two were positive by pp65 antigenemia assay and
12 were negative by both real-time PCR and pp65 anti-
genemia assay. One donor was positive only by real-
time PCR. Seventeen others were tested negative for
both pp65 antigen and HCMV DNA. Of the 19 unre-
lated (table 2) donor-recipient pairs, all recipients were
positive for the presence of both pp65 antigen and
HCMV DNA the results of which were ranging from 5 -
230 cells/2 × 10
5 leucocytes and copy numbers ranging
from 46 - 84,62,847 copies/ml respectively. Four of the
donors were positive for the presence of HCMV DNA
with copy numbers ranging from 14 - 458 copies/ml but
none were detected by pp65 antigenemia assay.
Results on the follow up samples
In sub-group I, all three recipients were followed up to
two months and became negative for HCMV viremia.
Fourteen among twenty seven patients in group II were
followed up. Six of them became negative. Three others
remained positive with an increasing real time PCR
count. Five others had varied HCMV copy numbers in
the samples. One patient belonging to group III was fol-
lowed up to second month and the pp65 count was
raised to 37 cells and real time value was 106457
copies/ml. One among the two in-group IV, patient was
followed up to three months and remained negative. Yet
another patient turned positive with 9092 copies/ml
during the second month and could not be followed up
further. Among the seven patients in group IV, one of
them was turned positive with 246 copies of HCMV/ml.
Overall a significant number of (66.6%) recipients
whose donors were negative developed a post transplant
HCMV infection (chi-square test p = 0.037%).
Correlation between pp65 and real time PCR results
Among the 76 kidney donors 58 (73.68%) were positive
for real time PCR and of the 56, 39 (51.0%) were posi-
tive for pp65 antigenemia with a range of 3-86 cells/2 ×
10
5 PBML. None of them were positive for pp65 antige-
nemia alone.
The real time copy numbers were higher among indi-
viduals having more than 10 cells/2 × 10
5 PBML. The
median HCMV copy number among them was 751.5
copy/ml and the mean was 276698.6 copy/ml. Among
patients with equal or less than 10 cells/2 × 10
5 PBML,
the mean copy number/ml was 2546 and the median
was 119 copies/ml. A significant positive correlation was
observed between the values of pp65 antigenemia and
qRT-PCR (paired t test = 0.003052).
Valgancyclovir treatment
Among the seventy-six renal transplant recipients fifty-
seven were positive for HCMV after transplantation. Of
the fifty-seven HCMV positives, thirty-three of them
Figure 1 Bar graph comparing the pp65 antigenemia values of
the 3 sub-groups belonging to group ‘A’. D- Donors. PRR- Pre-
Transplant Recipient specimens. PSR- Post - Transplant recipient
specimens.
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Page 3 of 7presented with symptoms of HCMV disease and were
treated with Valgancyclovir (Valgan/Valcept-450 mg/
tablet) and twenty-four were not treated with Valgancy-
clovir. “The exact number of pp65 positive cells/2 × 10
5
leucocytes PBMC and HCMV DNA copy numbers esti-
mated/ml is presented in table 2.”
Discussion
In our study among the seventy six donor recipient pairs
a significant number of the transplant recipients (66%)
developed HCMV infection post transplant. Fifty seven
( 7 5 % )o ft h e mw e r et e s t e dp o s i t i v ef o rH C M Vp o s t
transplant by real time PCR while thirty seven (49%) of
them were positive for HCMV by pp65 antigenemia
assay. Of the seventy six donors, eleven (14.47%) of
them were positive for HCMV by real time PCR while
one (1.3%) of them was positive for the virus by pp65
antigenemia assay. The exact source of HCMV detected
in the three recipients of sub-group I could assumed to
be the donor as they were negative prior transplantation.
Figure 2 Scatter plot comparing all 3 sub-groups of group ‘A’ based on pp65 antigenemia values. 1: D+/PRR-/PSR+. 2: D-/PRR-/PSR+. 3:
D+/PRR+/PSR+.
Figure 3 Bar graph showing % negativity in pp65 antigenemia
values among renal transplant recipients. D- Donors. PRR- Pre-
Transplant Récipient specimens. PSR- Post - Transplant récipient
spécimens.
Figure 4 Bar graph showing significantly high values of pp65
antigenemia among the recipients belonging to sub-group II
of group ‘A’. D- Donors. PRR- Pre- Transplant Récipient specimens.
PSR- Post - Transplant récipient spécimens.
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ents of sub-group II is probably due to the reactivation
of the latent virus present in them or other invasive
procedures that lead to transmission of HCMV. In the
sub-group III of Group A since the donor’s and the reci-
pient’s pre-transplantation sample were tested positive
for HCMV viremia the assumption that post-transplant
the recipient would develop a aggressive disease course
did not occur. Results analyzed from the various groups,
substantiate the fact that the HCMV DNA was present
among kidney donors and the rate of detection in our
study was 11.8%.
It is recommended that donors be screened for
HCMV serostatus to prevent adverse outcome of
HCMV disease in renal transplant patients. But the
lower survival of donor positive recipient positive (D+R
+) transplants rather than donor positive, recipient
negative (D+R-) and the absence of relationship between
CMV infection and acute cellular rejection have been
reported [6-8]. In our study we observed the detection
of HCMV DNA in large number of patients who along
with their donor did not have HCMV DNA prior trans-
plantation. HCMV detection in donors and recipients
will be a better method to assess the status as DNA
appears even before sero-conversation takes place.
Among the fifty seven HCMV positive recipients, only
thirty-three (58%) of them were treated with valgancy-
clovir since they had symptoms of active HCMV disease,
while twenty four of the recipients (42%) were not trea-
ted though they had HCMV DNA. Twenty two (39%) of
the transplant recipients with HCMV infection did not
develop symptomatic disease any time in the study per-
iod. Of the thirty nine recipients who were followed up,
only fourteen recipients with disease were put on treat-
ment (36%) while twenty five (64%) of the recipients
were not. As a result of the increased use of Gancyclovir
prophylaxis, the incidence and severity of CMV disease
is significantly reduced. However, there is an increasing
incidence of Gancyclovir resistant CMV infection.
Therefore treatment may be restricted to symptomatic
patients alone as the presence of HCMV DNA and low
count of pp65 antigenemia does not always lead to
development of disease process which was made evident
from the study. And also, the importance of giving pre-
emptive therapy to donors and transplant recipients
before transplantation may not be needed.
As reported earlier, patients belonging to sub-group II
of Group A had significantly more pp65 antigenemia
positive count when compared to patients belonging to
other groups [9]. Bossart et al has shown an 84% agree-
ment between pp65 antigenemia and quantitative assays
and pointed out an episode of active infection missed
o u tb yp p 6 5a n do t h e ri n s t a n c ew h e r et h ep a t i e n t
showed significant DNA-emia with very low pp65 anti-
genemia positivity [10]. The advantages and disadvan-
tages of pp65 and real time PCR in diagnosing HCMV
infection and disease were well described by Carini et al
2007 [11]. A median of 11 vs 30 cells pp65 positive cells
were reported among asymptomatic and symptomatic
patients respectively [11]. The utility of the real time
PCR technique for HCMV infection and usefulness of
both the technique in detection of symptomatic patients
Table 2 Results of HCMV performed on the 33 patients
treated for the disease
Patient
no
No of pp65 positive cells/2 × 10
5
leucocytes
HCMV DNA
detected copy/
ml
1 8 692
2. 20 775
3 86 8462847
4 78 3817
5 13 15386
6 25 20201
7 28 1851
8 35 647
9 25 724
10 14 1673
11 32 29768
12 38 75479
13 35 500
14 48 460
15 78 271
16 20 775
17 86 8462847
18 78 3817
19 230 30902
20 8 692
21 49 674
22 35 4849
23 7 47
24 27 337
25 3 334
26 22 7456
27 15 1411
28 40 24104
29 52 6756
30 20 2265
31 7 4937
32 0 3079
33. 32 29768
pp65 antigenemia assay and HCMV 2 × 10
5 leucocytes of peripheral blood
and human cytomegalovirus DNA copy numbers detected/ml in the 33 renal
transplant recipients who underwent valganciclovir treatment for symptomatic
disease showed presence of antigenemia in 32/33 patients.
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5 PBML
cells was considered a predictor of symptomatic infec-
tion [11]. The significant positive pp65 antigenemia
value quoted varies from equal or more than 5 to 30
cells. In our study predominantly a pp65 positive count
of equivalent and above 10 cells/2 × 10
5 and also
accompanied positive high DNA copy number corre-
lated well with the disease symptoms as observed
among the 33 symptomatic patients who were treated
with valganciclovir. Carni et al have shown that 29.1%
of symptomatic kidney transplanted patients had pp65
positivity as against 11.8% asymptomatic patients [11].
‘Minz et have reported that 14% patients with sympto-
matic HCMV disease tested positive by pp55 antigene-
mia [12]. There were 5 (14%) low-positive and 30 (86%)
high-positive patients and all high-positive patients were
presented with HCMV disease. According to Kim and
Kwan all patients who had an HCMV antigenemia titer
of higher than 50 per 400,000 leukocytes developed
HCMV-related symptoms and signs during the follow-
up period [13]. However, in our study, six symptomatic
patients had less than 10 positive cells per 2 × 10
5 leu-
cocytes/PBML.
In our study, a total of 32 among 33 patients, put on
treatment, tested positive for pp65 antigenemia assay.
Among the 32, six of them had a pp65 count of less
than 10 positive cells per 2 × 10
5 leucocytes. In three
patients, the count ranged between 10 and 20 positive
cells per 2 × 10
5 leucocytes. In others, the count was
more than 20 with the highest being 86 positive cells
per 2 × 10
5 leucocytes.
The prevalence of HCMV among renal transplant
patients was higher (20-60%) compared to western lit-
erature [14]. A study carried out in southern part of
India among renal transplant patients by application of
the quantitative PCR revealed asymptomatic viremia in
60-70% of patients at each sampling point [15]. However
seroprevalence data showed that 95% of healthy blood
donors tested positive for anti-HCMV IgG antibodies in
India [16].
In conclusion, the study observed the presence of
HCMV DNA among kidney donors. The recipients
develop HCMV infection even if the donors are negative
for HCMV. pp65 antigenemia and real time PCR, can
be applied as a qualitative measure to assess the HCMV
infection among renal transplant patient and to monitor
the prognosis. Treatment should be restricted to those
with HCMV disease.
Materials and methods
Study Design
Clinical specimens were investigated at L & T Micro-
biology Research Centre, Vision Research Foundation, in
Sankara Nethralaya, Chennai, India during September
2007 to August 2009. A total of two hundred and thirty
peripheral blood samples were processed and a prospec-
tive study was carried out in three groups of donor-
recipient pairs. Patients with Neutropenia, high degree
of renal dysfunction, were excluded from the study.
The mean age of the recipients was 48.5 year and the
female to male ratio was 2:3. The age range among reci-
pient males was 23 to 56 and female was 23 to 59. The
mean age of the donors was 36.48 and the female to
male ratio was 1.3: 1. The age range among donor male
was 26-60 and female was 22 to 55.
Group ‘A’ consisted of 39 kidney transplanted patients
and the corresponding donors. One hundred and fifty
six blood specimens were collected which included 117
samples from thirty-nine renal transplant recipients
before and month after transplantation and their corre-
sponding donors samples pre-transplantation. Thirty-
nine more blood samples were the follow up samples
collected from recipients after two months.
Group ‘B’ includes 18 more donors and the corre-
sponding 18 recipients who could not be followed up
one month after transplantation period. From this group
thirty-six samples were collected from donors pre-trans-
plantation and their corresponding recipients prior and
one-month post transplantation.
Group ‘C’ included 19 donors and 19 kidney trans-
plant recipients who were unrelated. A total of 38 blood
samples were collected one-month post transplant from
the recipients and pre-transplant samples were collected
from the donors. Pre-transplantation samples could not
be collected from the recipients.
Samples were collected in 2 ml EDTA vacutainer
tubes and were transported immediately to the labora-
tory from Kaliappa Renal Centre, Chennai. All speci-
mens were transported in their naïve form without any
transport medium. The blood specimens were processed
immediately for pp65, and real time PCR for HCMV
(qRT-PCR). The study was approved by both the insti-
tute’s research and ethics committee and informed con-
sent was obtained from the donors and the renal
transplant recipients who participated in the study.
Antigenemia assay
The pp65 antigenemia assay was carried out on smears
containing 2 × 10
5 leucocytes prepared from 5 ml of
EDTA anticoagulated blood within six hours of receipt
of the specimen. Smears were fixed in methanol for 10
minutes. Immunofluorescence staining was carried out
on the smears using pp65 staining kit obtained from
Argene SA, France. The smears were stained with
mouse monoclonal antibody (Argene SA, France); 0.5%
Evan’s blue (Hi-media, Mumbai), was used as a counter
stain. The smears were examined under fluorescent
microscope (Optiphot, Nikon, Japan) with blue filter.
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was defined to be positive for the assay and the result
w a se x p r e s s e da st h en u m b e ro fC M Vp p 6 5p o s i t i v e
cells per 2 × 10
5 leukocytes.
DNA Extraction
Nucleic acid was extracted from 0.2 ml of EDTA -
anticoagulated whole blood by using the Bioneer blood/
tissue kit (Bioneer Corporation, Daejeon, Korea) accord-
ing to the manufacturer’s instructions. DNA was eluted
from bioneer columns in a final volume of 200 μl of elu-
tion and was stored at -20°C until used. These extracted
DNA samples were used for quantitative PCR assays.
Real Time PCR Assay
Real-time PCR targeting the morphologically transform-
ing region mtr II sequence was applied onto the DNA
extracted from these specimens in Rotor gene Real time
PCR machine (Corbett Research, Australia) using pri-
mers and thermal profile described earlier [17]. The
intra-assay and inter-assay reproducibility were evalu-
ated using triplicates of plasmid dilutions (10
1,1 0
3 and
10
5) corresponding to an input of 2.5 × 10
3,2 . 5×1 0
5,
2.5 × 10
7 copies/ml per reaction in the same and four
independent runs respectively.
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